These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

511 related items for PubMed ID: 18576907

  • 1. Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
    Norgard NB, Stark JE.
    Pharmacotherapy; 2008 Jul; 28(7):920-31. PubMed ID: 18576907
    [Abstract] [Full Text] [Related]

  • 2. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 3. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS.
    J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
    [Abstract] [Full Text] [Related]

  • 4. Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction?
    McMurray JJ, Pfeffer MA, Swedberg K, Dzau VJ.
    Circulation; 2004 Nov 16; 110(20):3281-8. PubMed ID: 15545527
    [No Abstract] [Full Text] [Related]

  • 5. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan 16; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 6. Suppression of the renin-angiotensin-aldosterone system in chronic heart failure: choice of agents and clinical impact.
    Jorde UP.
    Cardiol Rev; 2006 Jan 16; 14(2):81-7. PubMed ID: 16493245
    [Abstract] [Full Text] [Related]

  • 7. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA, Movahed A.
    Rev Cardiovasc Med; 2005 Jan 16; 6(4):206-13. PubMed ID: 16379016
    [Abstract] [Full Text] [Related]

  • 8. A review of heart failure management in the elderly population.
    Cheng JW, Nayar M.
    Am J Geriatr Pharmacother; 2009 Oct 16; 7(5):233-49. PubMed ID: 19948300
    [Abstract] [Full Text] [Related]

  • 9. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy.
    Jneid H, Moukarbel GV, Dawson B, Hajjar RJ, Francis GS.
    Am J Med; 2007 Dec 16; 120(12):1090.e1-8. PubMed ID: 18060931
    [Abstract] [Full Text] [Related]

  • 10. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G, Gorini M, Maggioni AP, Di Lenarda A, Area Scompenso ANMCO, Firenze.
    G Ital Cardiol (Rome); 2007 Feb 16; 8(2):102-6. PubMed ID: 17402354
    [Abstract] [Full Text] [Related]

  • 11. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T, Takeshita A.
    Nihon Rinsho; 2003 May 16; 61(5):801-6. PubMed ID: 12755006
    [Abstract] [Full Text] [Related]

  • 12. Mechanistic and clinical rationales for using beta-blockers in heart failure.
    Bristow MR.
    J Card Fail; 2000 Jun 16; 6(2 Suppl 1):8-14. PubMed ID: 10908093
    [Abstract] [Full Text] [Related]

  • 13. Treatments that improve outcome in the patient with heart failure, left ventricular systolic dysfunction, or both after acute myocardial infarction.
    Weir R, McMurray JJ.
    Heart; 2005 May 16; 91 Suppl 2(Suppl 2):ii17-20; discussion ii31, ii43-8. PubMed ID: 15831602
    [Abstract] [Full Text] [Related]

  • 14. A hard look at angiotensin receptor blockers in heart failure.
    Gring CN, Francis GS.
    J Am Coll Cardiol; 2004 Nov 02; 44(9):1841-6. PubMed ID: 15519017
    [Abstract] [Full Text] [Related]

  • 15. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA, Wendt C, Saborowski F.
    Fiziol Cheloveka; 2005 Nov 02; 31(6):97-105. PubMed ID: 16366159
    [Abstract] [Full Text] [Related]

  • 16. Inhibiting the renin-angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials.
    Tokmakova M, Solomon SD.
    Curr Opin Cardiol; 2006 Jul 02; 21(4):268-72. PubMed ID: 16755193
    [Abstract] [Full Text] [Related]

  • 17. beta-Blocker therapy in heart failure.
    Doughty RN.
    Heart Fail Monit; 2000 Jul 02; 1(1):2-7. PubMed ID: 12634875
    [Abstract] [Full Text] [Related]

  • 18. Use of valsartan in post-myocardial infarction and heart failure patients.
    Liu PP, Maggioni A, Velazquez EJ.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun 02; 7 Suppl 1():S19-22. PubMed ID: 16986231
    [Abstract] [Full Text] [Related]

  • 19. Aldosterone receptor antagonism and heart failure: insights from an outpatient clinic.
    Mariotti R, Borelli G, Coceani M, Zingaro S, Barison A, Morelli I, Rondinini L.
    J Clin Pharm Ther; 2008 Aug 02; 33(4):349-56. PubMed ID: 18613852
    [Abstract] [Full Text] [Related]

  • 20. Interaction of beta-blockers and angiotensin receptor blockers/ACE inhibitors in heart failure.
    Cohn JN.
    J Renin Angiotensin Aldosterone Syst; 2003 Sep 02; 4(3):137-9. PubMed ID: 14608516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.